Journal of Investigative Dermatology (2015) 135, 1007–1015; doi:10.1038/jid.2014.516; published online 8 January 2015 / 京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第18890号 / 医博第4001号 / 新制||医||1009(附属図書館) / 31841 / 京都大学大学院医学研究科医学専攻 / (主査)教授 生田 宏一, 教授 髙折 晃史, 教授 河本 宏 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

γδ T cells are unique players in shaping immune responses, lying at the intersection between innate and adaptive immunity. Unlike conventional αβ T cells, γδ T cells largely populate non-lymphoid peripheral tissues, demonstrating tissue specificity, and they respond to ligands in an MHC-independent manner. γδ T cells display rapid activation and effector functions, with a capacity for cytotoxic anti-tumour responses and production of inflammatory cytokines such as IFN-γ or IL-17. Their rapid cytotoxic nature makes them attractive cells for use in anti-cancer immunotherapies. However, upon transformation, γδ T cells can give rise to highly aggressive lymphomas. These rare malignancies often display poor patient survival, and no curative therapies exist. In this review, we discuss the diverse roles of γδ T cells in immune surveillance and response, with a particular focus on cancer immunity. We summarise the intriguing dichotomy between pro- and anti-tumour functions of γδ T cells in solid and haematological cancers, highlighting the key subsets involved. Finally, we discuss potential drivers of γδ T-cell transformation, summarising the main γδ T-cell lymphoma/leukaemia entities, their clinical features, recent advances in mapping their molecular and genomic landscapes, current treatment strategies and potential future targeting options.

京都大学 / 0048 / 新制・課程博士 / 博士(医科学) / 甲第19405号 / 医科博第65号 / 新制||医科||5(附属図書館) / 32430 / 京都大学大学院医学研究科医科学専攻 / (主査)教授 河本 宏, 教授 斎藤 通紀, 教授 竹内 理 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DGAM